<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795366</url>
  </required_header>
  <id_info>
    <org_study_id>20060949</org_study_id>
    <nct_id>NCT00795366</nct_id>
  </id_info>
  <brief_title>Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients</brief_title>
  <acronym>AVP</acronym>
  <official_title>Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic brain injury (TBI) is among the leading causes of trauma death and disability in
      both civilian and military populations. The damage that occurs at the instant of trauma
      cannot be modified; the secondary injuries that occur afterward are the impediments to
      recovery and can be influenced by the physician. Cerebral ischemia is the most important
      secondary event that determines outcome following TBI. To minimize ischemic episodes once the
      patient has arrived at the hospital, most treatments are aimed at optimizing cerebral
      perfusion pressure (CPP). The cornerstones of these treatments include mannitol, to reduce
      intracranial pressure (ICP), and catecholamines, such as phenylephrine (PE), to increase mean
      arterial pressure (MAP), but these agents have undesired side effects. Nevertheless, once
      they lose potency, there are few alternatives. The main objective of this proposal to develop
      a new therapeutic option for CPP management in TBI patients using arginine vasopressin (AVP).

      AVP is the endogenous anti-diuretic hormone. It is FDA-approved for use in the diagnosis and
      treatment of diabetes insipidus, for the prevention and treatment of post-operative abdominal
      distention, and in abdominal radiography to dispel interfering gas shadows. It has been used
      off-label for several other conditions. There is minimal information on its therapeutic
      potential after TBI. The investigators have demonstrated that AVP during fluid resuscitation
      rapidly restored hemodynamics, CPP, and improves acute survival in a clinically-relevant
      model of TBI. The investigators observed similar short term benefits after chest and liver
      trauma. Nevertheless, AVP has actions that could mask any short term benefit. The
      investigators have already defined risks and benefits of AVP therapy, relative to PE, in four
      different clinically-relevant laboratory model. The investigators now plan to evaluate this
      new therapy relative to the current evidence-based guideline for CPP management in TBI
      patients.

      The working hypothesis is that the risk/benefit profile for AVP is equal, or superior to, PE
      at equi-effective doses for the management of CPP following TBI. A corollary is that a higher
      CPP can be safely tolerated with AVP vs catecholamines.

      THE INVESTIGATORS AIM TO: Determine whether AVP is safe and effective to maintain CPP = 60 mm
      Hg in TBI patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, open-label clinical trial comparing vasopressin and
      catecholamines for cerebral perfusion pressure (CPP) control after a traumatic brain injury
      (TBI).

      Once a neurosurgeon is consulted for a patient presenting with a TBI, they will review entry
      criteria and refer to study personnel to obtain informed consent.

      After informed consent, subjects will be randomized into one of the 2 groups to receive
      either a catecholamine at the discretion of the attending physicians or vasopressin (AVP). A
      6 hour dose of non-study drug will be permitted prior to initiation of study drug. The amount
      of study drug will be titrated to maintain cerebral perfusion pressure within normal limits.
      Subjects will be followed until they can maintain their CPP without vasopressor medication.
      Data collection will include amount and duration of vasopressor therapy and resulting
      cerebral perfusion pressure and time until successful weaning from vasopressor therapy.

      All subsequent clinical care will be at the discretion of the attending physician.

      The standard protocol/procedure for the discontinuation of drugs in each arm of the study is
      as follows: Vasopressors are discontinued in a step-wise fashion, regardless of the specific
      agent or the specific ICU patient population. In patients with severe traumatic brain injury
      (TBI), cerebral perfusion pressure (CPP) is maintained between 60 and 70 mmHg with
      vasopressors. When intracranial pressure (ICP) begins to correct (decrease), vasopressors are
      titrated downward slowly to maintain CPP. This continues until ICP is normalized and systemic
      hemodynamics are able to support a normal CPP. At this point, vasopressors are withdrawn
      completely. This process is standard regardless of the choice of vasopressor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time ICP &gt;20</measure>
    <time_frame>The number of hours during the first 5 days of intracranial pressure monitoring</time_frame>
    <description>The number of hours that participants remained with intracranial pressure above 20 mmHg</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>AVP, arginine vasopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vasopressin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Catecholamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levophed, dopamine, phenylephrine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arginine vasopressin</intervention_name>
    <description>Titrated to cerebral perfusion pressure greater than 60 mm Hg</description>
    <arm_group_label>AVP, arginine vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard catecholamine</intervention_name>
    <description>Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.</description>
    <arm_group_label>Standard Catecholamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18 yrs,

          -  Primary admission to the hospital within 8 h after injury

          -  Closed head injury

          -  Potential for intracranial pressure monitoring

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  Hemodynamic instability after initial resuscitation

          -  Vasopressor therapy for greater than 6 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth G Proctor, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ryder Trauma Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dudkiewicz M, Proctor KG. Tissue oxygenation during management of cerebral perfusion pressure with phenylephrine or vasopressin. Crit Care Med. 2008 Sep;36(9):2641-50. doi: 10.1097/CCM.0b013e3181847af3.</citation>
    <PMID>18679110</PMID>
  </reference>
  <reference>
    <citation>Sanui M, King DR, Feinstein AJ, Varon AJ, Cohn SM, Proctor KG. Effects of arginine vasopressin during resuscitation from hemorrhagic hypotension after traumatic brain injury. Crit Care Med. 2006 Feb;34(2):433-8.</citation>
    <PMID>16424725</PMID>
  </reference>
  <reference>
    <citation>Feinstein AJ, Cohn SM, King DR, Sanui M, Proctor KG. Early vasopressin improves short-term survival after pulmonary contusion. J Trauma. 2005 Oct;59(4):876-82; discussion 882-3.</citation>
    <PMID>16374276</PMID>
  </reference>
  <reference>
    <citation>Feinstein AJ, Patel MB, Sanui M, Cohn SM, Majetschak M, Proctor KG. Resuscitation with pressors after traumatic brain injury. J Am Coll Surg. 2005 Oct;201(4):536-45.</citation>
    <PMID>16183491</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <results_first_submitted>December 1, 2014</results_first_submitted>
  <results_first_submitted_qc>December 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2014</results_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Kenneth Proctor</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>TBI, trauma, brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AVP, Arginine Vasopressin</title>
          <description>Vasopressin: Titrated to cerebral perfusion pressure greater than 60 mm Hg</description>
        </group>
        <group group_id="P2">
          <title>Standard Catecholamine</title>
          <description>Standard catecholamine: Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AVP, Arginine Vasopressin</title>
          <description>Vasopressin, arginine vasopressin: Titrated to cerebral perfusion pressure greater than 60 mm Hg</description>
        </group>
        <group group_id="B2">
          <title>Standard Catecholamine</title>
          <description>Standard catecholamine: Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="16"/>
                    <measurement group_id="B2" value="38" spread="18"/>
                    <measurement group_id="B3" value="39" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ISS (Injury Severity Score)</title>
          <description>ISS is an anatomical scoring system that provides an overall score for patients with multiple injuries. Each injury is assigned an Abbreviated Injury Scale (AIS) score and is allocated to one of six body regions (Head, Face, Chest, Abdomen, Extremities (including Pelvis), External). Only the highest AIS score in each body region is used. The 3 most severely injured body regions have their score squared and added together to produce the ISS score. The ISS scores range from 1 to 75, being one the least severe and 75 the most severe trauma injury.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="9"/>
                    <measurement group_id="B2" value="28" spread="10"/>
                    <measurement group_id="B3" value="28" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time ICP &gt;20</title>
        <description>The number of hours that participants remained with intracranial pressure above 20 mmHg</description>
        <time_frame>The number of hours during the first 5 days of intracranial pressure monitoring</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>AVP, Arginine Vasopressin</title>
            <description>Vasopressin, arginine vasopressin: Titrated to cerebral perfusion pressure greater than 60 mm Hg</description>
          </group>
          <group group_id="O2">
            <title>Standard Catecholamine</title>
            <description>Standard catecholamine: Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.</description>
          </group>
        </group_list>
        <measure>
          <title>Time ICP &gt;20</title>
          <description>The number of hours that participants remained with intracranial pressure above 20 mmHg</description>
          <population>Intent-to-Treat</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.8"/>
                    <measurement group_id="O2" value=".9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the primary study period as the first 5 days of intracranial pressure monitoring while outcome data was also collected from admission until discharge from the hospital.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AVP, Arginine Vasopressin</title>
          <description>Vasopressin, arginine vasopressin: Titrated to cerebral perfusion pressure greater than 60 mm Hg</description>
        </group>
        <group group_id="E2">
          <title>Standard Catecholamine</title>
          <description>Standard catecholamine: Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kenneth Proctor, PhD, Professor of Surgery</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-585-1178</phone>
      <email>kproctor@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

